<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762476</url>
  </required_header>
  <id_info>
    <org_study_id>TM&amp;R-0062-08-TXC</org_study_id>
    <secondary_id>CS990108</secondary_id>
    <secondary_id>13805</secondary_id>
    <nct_id>NCT00762476</nct_id>
  </id_info>
  <brief_title>Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses</brief_title>
  <official_title>A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II EFFICACY TRIAL OF AV LOTION (FORMULA NO. 3804-250A) FOR THE PREVENTION OF COLD ILLNESS IN HUMAN SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Dial Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hill Top Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>TKL Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Dial Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of 3804-250A in the prevention of the
      common cold. The study will also evaluate whether 3804-250A prevents rhinovirus infection, a
      virus that causes many common colds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rhinovirus infections are the most frequent cause up to 80% of cold illnesses during the fall
      rhinovirus season. While viral upper respiratory infections are generally mild and
      self-limited, they are associated with an enormous economic burden both in lost productivity
      and in expenditures for treatment. Rhinovirus infection is frequently associated with medical
      complications that have substantial morbidity such as acute otitis media and exacerbation of
      asthma.

      Marketed treatment options for rhinovirus consist primarily of symptomatic cold remedies have
      only modest effects on specific cold symptoms. 3804-250A is under investigation for the
      prevention of rhinovirus infection by interruption of person-to-person transmission appears
      to be technologically and economically feasible.

      The study is a randomized, double-blind, Placebo controlled, multi-site, parallel design
      clinical trial conducted in the natural setting. The study will be conducted during a 10-week
      period during the fall rhinovirus epidemic season. Healthy, normal subjects will be recruited
      and randomly assigned to the AV Lotion or Placebo control group. Subjects will use the
      assigned test product on a defined schedule and will record the presence of cold illness
      symptoms daily. Subjects will return to the study site every week during the study for review
      and clarification of study diary entries, for review and assessment of compliance, for
      specimen collection for rhinovirus PCR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses.</measure>
    <time_frame>10 weeks</time_frame>
    <description>Comparison of the total number of incidence of cold illnesses over the course of the study per 100 subjects in each treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rhinovirus Infections.</measure>
    <time_frame>10 weeks</time_frame>
    <description>The incidence of rhinovirus infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinovirus-associated Colds</measure>
    <time_frame>10 weeks</time_frame>
    <description>The incidence of rhinovirus-associated cold illnesses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3804-250A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3804-250A</intervention_name>
    <description>topical product
apply 2 pumps
apply at least every 4 hours or after hand washing</description>
    <arm_group_label>3804-250A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3804-291</intervention_name>
    <description>topical
apply 2 pumps
apply at least every 4 hours or after hand washing</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy normal

          -  good general health

        Exclusion Criteria:

          -  pregnancy

          -  insulin dependent diabetes

          -  daily smoker

          -  skin disease on the hands/wrists

          -  immunological disorders

          -  occupation involving frequent handwashing

          -  common cold symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald B Turner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael E Casser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TKL Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Research, Inc.</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>February 8, 2012</results_first_submitted>
  <results_first_submitted_qc>March 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2012</results_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cold, common</keyword>
  <keyword>rhinovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Modified AV Lotion without active ingredients.</description>
        </group>
        <group group_id="P2">
          <title>3804-250A</title>
          <description>Experimental AV Lotion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>antibiotic use</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance with study visits</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Seasonal allergies</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Modified AV Lotion without active ingredients.</description>
        </group>
        <group group_id="B2">
          <title>3804-250A</title>
          <description>Experimental AV Lotion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="206"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="411"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="14.56"/>
                    <measurement group_id="B2" value="36.2" spread="14.23"/>
                    <measurement group_id="B3" value="36.7" spread="14.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses.</title>
        <description>Comparison of the total number of incidence of cold illnesses over the course of the study per 100 subjects in each treatment group</description>
        <time_frame>10 weeks</time_frame>
        <population>All efficacy analyses were performed on the intent-to-treat (ITT).The ITT population included all enrolled subjects who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Modified AV Lotion without active ingredients</description>
          </group>
          <group group_id="O2">
            <title>3804-250A</title>
            <description>Experimental AV Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses.</title>
          <description>Comparison of the total number of incidence of cold illnesses over the course of the study per 100 subjects in each treatment group</description>
          <population>All efficacy analyses were performed on the intent-to-treat (ITT).The ITT population included all enrolled subjects who received study treatment.</population>
          <units>cold illnesses per 100 subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.5000</p_value>
            <method>Poisson regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinovirus Infections.</title>
        <description>The incidence of rhinovirus infections</description>
        <time_frame>10 weeks</time_frame>
        <population>All efficacy analyses were performed on the intent-to-treat (ITT).The ITT population included all enrolled subjects who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Modified AV Lotion without active ingredients.</description>
          </group>
          <group group_id="O2">
            <title>3804-250A</title>
            <description>Experimental AV Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinovirus Infections.</title>
          <description>The incidence of rhinovirus infections</description>
          <population>All efficacy analyses were performed on the intent-to-treat (ITT).The ITT population included all enrolled subjects who received study treatment.</population>
          <units>rhinovirus infections per 100 subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7"/>
                    <measurement group_id="O2" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.5000</p_value>
            <method>Poisson regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinovirus-associated Colds</title>
        <description>The incidence of rhinovirus-associated cold illnesses.</description>
        <time_frame>10 weeks</time_frame>
        <population>All efficacy analyses were performed on the intent-to-treat (ITT).The ITT population included all enrolled subjects who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Modified AV Lotion without active ingredients.</description>
          </group>
          <group group_id="O2">
            <title>3804-250A</title>
            <description>Experimental AV Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinovirus-associated Colds</title>
          <description>The incidence of rhinovirus-associated cold illnesses.</description>
          <population>All efficacy analyses were performed on the intent-to-treat (ITT).The ITT population included all enrolled subjects who received study treatment.</population>
          <units>RV-associated cold illnesses per 100 sub</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3451</p_value>
            <method>Poisson regression</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Modified AV Lotion without active ingredients.</description>
        </group>
        <group group_id="E2">
          <title>3804-250A</title>
          <description>Experimental AV Lotion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <description>Injury secondary to motor vehicle accident</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <description>Injury secondary to motor vehicle accident</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <description>Affected C1 &amp; C3 vertebra. Injury secondary to motor vehicle accident.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <description>Left side of neck and head affected. Injury secondary to motor vehicle accident.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>excoriation</sub_title>
                <description>Left forehead and left cheek affected. Injury secondary to motor vehicle accident.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="206"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="206"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>thermal burn</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="206"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="205"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period 1 year after study completion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ronald Turner</name_or_title>
      <organization>University of Virginia</organization>
      <phone>(434) 243-9864</phone>
      <email>RBT2N@hscmail.mcc.virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

